Recent Updates
Recently added Catalysts
TNDM Negative Sentiment Score: 25/100

TANDEM ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been initiated against Tandem Diabetes Care, Inc. in the U.S. District Court for the Southern District of California. The lawsuit pertains to alleged misleading information regarding the company’s revenue projections for 2022, which were substantially revised downward after initial optimistic forecasts. As a result, Tandem's stock experienced a significant drop of 30.4%. Investors have until November 7, 2023, to apply for lead plaintiff status in the lawsuit, emphasizing potential financial impacts on those who purchased shares during the specified period.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Tandem Diabetes Care, Inc.
  • Defendants allegedly provided misleading information about revenue projections.
  • The company's stock dropped 30.4% following a negative earnings forecast.
  • Challenges cited include increased competition, COVID complications, and inflation.

Full Press Release Details

NEW YORK, Oct. 29, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Tandem securities between August 3, 2022 and November 2, 2022, both dates inclusive (the “Class Period”). Investors have until November 7, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022. On August 2, 2022, Tandem estimated annual sales “to be in the range of $835 million to $845 million, which represents an annual growth of 19 percent to 20 percent compared to 2021.” Defendants provided these statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts.
According to the complaint, the truth emerged on November 2, 2022, when Tandem, in an investment call and Form 8-K filing, revised its 2022 forecast downward to $800 to $805 million. Reasons stated for the scale back included increased competition in the diabetes care sector, complications due to the COVID pandemic, and macroeconomic factors such as inflation. Investors and analysts reacted immediately to Tandem’s revised guidance. The price of Tandem’s common stock declined dramatically. On November 2, 2022, Tandem closed at $51.34; however, on November 3, 2022, Tandem closed at $35.72 – a one-day decline of 30.4%.
If you purchased or otherwise acquired Tandem shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the class action lawsuit against Tandem Diabetes Care about?

The lawsuit claims Tandem misled investors about its projected 2022 revenue.

What was Tandem's initial sales estimate for 2022?

Tandem initially estimated 2022 sales between $835 million and $845 million.

When did Tandem revise its sales forecast?

Tandem revised its 2022 sales forecast on November 2, 2022.

What caused Tandem's stock price to drop?

The stock price fell due to revised sales guidance and increased competition.

How can I contact Bragar Eagel & Squire for more information?

You can email investigations@bespc.com or call (212) 355-4648.

Last updated: Oct 30, 2023